BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29330728)

  • 1. Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study.
    Benbow JH; Elam AD; Bossi KL; Massengill DL; Brandon-Warner E; Anderson WE; Culberson CR; Russo MW; deLemos AS; Schrum LW
    Dig Dis Sci; 2018 Mar; 63(3):653-664. PubMed ID: 29330728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Golgi protein 73 levels predict prognosis of HCV-related hepatic fibrosis.
    Liu L; Al-Dhamin Z; Yuan X; Cui L; Yang Y; Zhao W; Zhang Y; Fu N; Nan Y
    Histol Histopathol; 2020 Nov; 35(11):1309-1318. PubMed ID: 33063838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
    van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
    Bashir MH; Fazili J; Madhoun MF; Kanagala R; Chen S; Nusrat S
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):296-301. PubMed ID: 29200006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis.
    Ponziani FR; Putignani L; Paroni Sterbini F; Petito V; Picca A; Del Chierico F; Reddel S; Calvani R; Marzetti E; Sanguinetti M; Gasbarrini A; Pompili M
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1301-1311. PubMed ID: 30345704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis.
    Malik R; Lai M; Sadiq A; Farnan R; Mehta S; Nasser I; Challies T; Schuppan D; Afdhal N
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1562-8. PubMed ID: 20796156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited reliability of five non-invasive biomarkers in predicting hepatic fibrosis in chronic HCV mono-infected patients opposed to METAVIR scoring.
    Elesawy BH; Abd El Hafez A; Dorgham LS; El-Askary A
    Pathol Res Pract; 2014 Dec; 210(12):922-8. PubMed ID: 25123964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study.
    Bruno S; Crosignani A; Facciotto C; Rossi S; Roffi L; Redaelli A; de Franchis R; Almasio PL; Maisonneuve P
    Hepatology; 2010 Jun; 51(6):2069-76. PubMed ID: 20196120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
    Martinez SM; Fernández-Varo G; González P; Sampson E; Bruguera M; Navasa M; Jiménez W; Sánchez-Tapias JM; Forns X
    Aliment Pharmacol Ther; 2011 Jan; 33(1):138-48. PubMed ID: 21083589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.
    Lackner C; Struber G; Liegl B; Leibl S; Ofner P; Bankuti C; Bauer B; Stauber RE
    Hepatology; 2005 Jun; 41(6):1376-82. PubMed ID: 15915455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic hepatitis C].
    Grammatikos G; Sarrazin C
    Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C.
    Hernández-Bartolomé Á; López-Rodríguez R; Borque MJ; González-Moreno L; Real-Martínez Y; García-Buey L; Moreno-Otero R; Sanz-Cameno P
    World J Gastroenterol; 2016 Nov; 22(44):9744-9751. PubMed ID: 27956798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
    Schmid P; Bregenzer A; Huber M; Rauch A; Jochum W; Müllhaupt B; Vernazza P; Opravil M; Weber R;
    PLoS One; 2015; 10(9):e0138838. PubMed ID: 26418061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
    El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
    Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of genetic polymorphism -670A>G in the Fas gene and serum markers AST platelet ratio index, AST/ALT with significant fibrosis and cirrhosis in chronic hepatitis C.
    Deghady A; Abdou A; El-Neanaey WA; Diab I
    Genet Test Mol Biomarkers; 2012 Jun; 16(6):531-5. PubMed ID: 22352690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic accuracy of the Forns index, platelet count and AST to Platelet Ratio Index derived fibrosis index for the prediction of Hepatitis C virus-related significant liver fibrosis and cirrhosis.
    Kayadibi H; Yasar B; Ozkara S; Serdar MA; Kurdas OO; Gonen C
    Scand J Clin Lab Invest; 2014 Apr; 74(3):240-7. PubMed ID: 24460024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.